Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Masahiko ShimuraShigehiko KitanoNahoko OgataYoshinori MitamuraHideyasu OhHaruka OchiShino OhsawaAkito Hirakatanull nullPublished in: Japanese journal of ophthalmology (2023)
Consistent with global results, faricimab up to Q16W offered durable vision gains and improved anatomic and disease-specific outcomes among Japanese patients with DME.